Welcome to our dedicated page for PERRIGO news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on PERRIGO stock.
Perrigo Company plc reports recurring developments as a pure-play consumer health company focused on over-the-counter self-care products, store-brand private label offerings, and branded health and wellness products primarily in North America and Europe. Company updates cover operating results from continuing operations, category performance, dividends, investor presentations, and portfolio actions under its Three-S plan to stabilize, streamline, and strengthen the business.
News also addresses Perrigo's product-category reporting and brand momentum across Self Care and Specialty Care, including names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®. Recent corporate developments include the completed divestiture of the Dermacosmetics business and the use of portfolio proceeds for balance-sheet debt reduction.
Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Murray S. Kessler, along with CFO Ray Silcock, will participate in investor meetings at the Barclays Global Consumer Staples Conference on September 9, 2021. No formal presentation will be made. As a leader in providing affordable self-care products, Perrigo is the top store brand OTC player in the U.S. and ranks among the top 10 OTC companies in Europe. The company's focus on consumer health solutions positions it well within the competitive landscape.
Perrigo Company plc (NYSE: PRGO) reported a 3.4% increase in net sales for Q2 2021, totaling $981 million, driven by growth across most businesses, despite a weak cough/cold season. However, adjusted diluted EPS fell 15.3% to $0.50 due to higher input costs and reinstated marketing expenditures. The company reaffirmed its 2021 sales guidance, anticipating organic growth of 3%, although EPS expectations were adjusted to the lower end of $2.50 to $2.70 as inflationary pressures persist. Despite challenges, management expresses optimism for future sales recovery and growth opportunities.
Perrigo Company plc (NYSE: PRGO) has declared a quarterly dividend of $0.24 per share, scheduled for payment on September 21, 2021. Shareholders of record as of September 3, 2021 will receive this dividend. The company is noted for providing quality, affordable self-care products and is a leader in the U.S. over-the-counter market, offering more than 9,000 SKUs. The announcement highlights Perrigo's commitment to shareholder returns while emphasizing its strong position in the OTC health market.
Perrigo Company plc (NYSE; TASE: PRGO) is set to disclose its second quarter 2021 financial results on August 11, 2021, at 8:00 A.M. (EDT). The results will be followed by a conference call available via webcast on the investor relations section of their website. Perrigo is a leading provider of affordable OTC health and wellness products, holding a significant market position as the largest store brand OTC player in the U.S. and a Top 10 OTC company in Europe.
Perrigo Company plc (NYSE: PRGO) has successfully completed the sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion. This strategic divestiture marks a significant milestone in Perrigo's transformation into a leading global consumer self-care entity. CEO Murray S. Kessler emphasized the company's commitment to enhancing self-care product offerings, which has positioned Perrigo as the largest store brand OTC player in the U.S. and a top OTC company in Europe. The company aims to leverage its resources for future growth.
Perrigo Company plc (NYSE: PRGO) announced that President and CEO, Murray S. Kessler, along with CFO, Ray Silcock, will participate in several investor meetings. These include the Barclays Consumer Spring Symposium on May 25, the Oppenheimer 21st Annual Consumer Growth and Ecommerce Conference on June 16 at 9:05 AM EDT, and the Evercore ISI Consumer & Retail Summit on June 17 at 2:45 PM EDT. Investors can find webcasts of these presentations on Perrigo's website.
Perrigo Company plc has agreed to sell its over-the-counter (OTC) businesses in Mexico and Brazil to Advent International. This strategic move aims to enhance margins and is part of Perrigo's Project Momentum cost savings initiative. The sale, expected to finalize in the second half of 2021, follows a review indicating insufficient scale in Latin America. In FY2020, these businesses generated $85 million in sales but were considered dilutive to Perrigo's growth targets. The transaction is anticipated to be margin accretive, with no impact on adjusted diluted earnings per share for 2021.
Perrigo Company plc (PRGO) reported Q1 2021 net sales of $1.01 billion, down 6.8% year-over-year due to pandemic-related pantry loading. Cough/cold season impacts led to a 10.9% decline in organic growth. Adjusted diluted EPS decreased 25.4% to $0.50, compared to $0.67 in Q1 2020. The company reaffirmed its fiscal 2021 outlook, targeting 3% organic sales growth and $2.50-$2.70 adjusted EPS. New partnerships and increased retail foot traffic are expected to support a strong second half of the year.
Perrigo Company plc (NYSE; TASE: PRGO) will announce its fiscal first quarter financial results on May 11, 2021. There will be a conference call at 8:00 a.m. (EDT) to discuss these results, accessible via webcast or phone. Perrigo is the largest store brand OTC player in the U.S. and is also a top OTC company in Europe, offering over 9,000 SKUs and 200 branded products. The release emphasizes the company's commitment to affordable self-care products, while also providing a cautionary note about potential risks affecting future performance.
Perrigo Company plc (NYSE: PRGO) announced a quarterly dividend of $0.24 per share, set for payment on June 22, 2021 to shareholders of record by June 4, 2021. As a prominent provider of quality self-care products, Perrigo is a leader in the U.S. store brand OTC market and is among the top five OTC companies in Europe, with over 200 branded products across 28 countries. The announcement reflects the company's ongoing commitment to returning value to its shareholders while maintaining significant market presence.